Key facts
- Notable investors include Timesbole, Jiangsu Xinzhi Equity Investment Management, Jiangsu Dongbuzhou Venture Capital, Nantong Blue Bay Ventures, Nantong Science and Technology Innovation Investment Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Haitai Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Haitai Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Haitai Bio
Developer of animal vaccines designed for aquaculture and animal husbandry industry. The company develops vaccines, therapeutic proteins, and diagnostic solutions through proprietary technologies such as epitope-targeted binding proteins and reverse encapsulation methods, enabling the aquaculture and livestock markets to improve disease resistance, reduce mortality rates, enhance productivity, and maintain sustainable farming practices
- Sector
- Healthcare
- HQ
- Nantong, China
- Founded
- 2017
- Ownership
- Privately Held (backing)
Haitai Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Haitai Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Haitai Bio in its N-PORT filings yet. We sweep new filings monthly.